VC Firm SR One Closes Sophomore Fund at $600M to Build “Elite Biotechnology Companies”
Life sciences venture capital firm SR One has raised $600 million, exceeding its $500 million target, for its second fund supporting emerging startups in the biotech space.
The new fund is substantially larger than the first they raised in their spin out in 2020 after backing biotech companies for decades at UK pharmaceutical giant GlaxoSmith Kline.
With the second fund, SR One will continue to invest in a mix of new companies, early-stage firms and later opportunities that have the potential to address significant gaps in current treatment.
“We seek to partner with entrepreneurs building elite biotechnology companies, and we look forward to the potential development of new medicines for patients that Fund II may help bring to the market,” said Simeon George, MD, Co-Founder and Chief Executive Officer at SR One.
The firm says it has invested in more than 20 companies on both sides of the Atlantic. Its portfolio companies include cancer and immunology biotech Odyssey Therapeutics and cancer drug developer Rezo Therapeutics.
SR One, which is based in Redwood City, CA, and has additional offices in the Philadelphia area and London, manages approximately $1.5 billion in assets.
